Stay updated on SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.

Latest updates to the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page now displays Revision: v3.6.5, replacing the previous Revision: v3.6.4. This signals a newer site revision or template update.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating an internal platform update; no visible changes to study details or layout are indicated by the changes provided.SummaryDifference0.0%

- Check43 days agoChange DetectedA new revision tag, v3.6.3, was added to the page, replacing the previous v3.6.2. This indicates an updated version of the study record.SummaryDifference0.0%

- Check50 days agoChange DetectedThe page revision tag changed from v3.6.0 to v3.6.2, indicating a version update of the study record. No substantive study content or user-facing details were modified.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page adds a recruitment status note signaling that participants are no longer being sought, and adds new help and navigation sections (How to Read a Study Record, Common Questions, How to Join a Study). It also updates the Intervention/Treatment heading formatting and the site revision label to v3.6.0.SummaryDifference0.4%

- Check72 days agoChange DetectedThe page revision has been updated from v3.5.4 to v3.5.5, representing a new patch/version of the ClinicalTrials.gov record. This likely accompanies small edits or improvements to the page layout or metadata, while the study details themselves remain unchanged.SummaryDifference0.0%

Stay in the know with updates to SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.